The Peptide NewsroomPeptide research, industry and supply-chain headlines

GLP-1 Drugs Linked to Fewer Hospitalizations in Adults With Alcohol Use Disorder, But Data Is Retrospective

Topic card: glp-1

A retrospective cohort study published in the European Journal of Internal Medicine reports that adults with alcohol use disorder and overweight or obesity who started a GLP-1 receptor agonist had lower odds of hospitalization, death and major cardiovascular events at one year. The analysis covers 163,681 people drawn from electronic health records.

GLP-1 receptor agonists are the drug class that includes semaglutide and tirzepatide, prescribed for obesity and type 2 diabetes. Researchers have been circling a secondary question for a while now: whether the same drugs blunt alcohol consumption, and whether that translates into fewer trips to the hospital. This is one of the larger attempts to answer it with real-world records rather than anecdote.

How the cohorts were built

The authors used the TriNetX research network, enrolling adults aged 18 and over between January 2015 and December 2024 and following them through December 2025. People with prior GLP-1 use, cancer, or a non-nicotine substance use disorder diagnosis were excluded.

Of the 163,681 participants, mean age 53.7 and 35.6% female, 10,445 (6.4%) started a GLP-1 receptor agonist. Inverse probability of treatment weighting based on propensity scores was used to balance baseline characteristics between the two groups.

Key results

At one year, the treatment cohort had lower odds of all-cause hospitalization (adjusted odds ratio 0.28, 95% CI 0.28 to 0.29) and alcohol-related hospitalization (aOR 0.20, 95% CI 0.20 to 0.21). Odds of death were also lower (aOR 0.20, 95% CI 0.19 to 0.21), as were major cardiovascular events (aOR 0.72, 95% CI 0.71 to 0.74).

Exploratory analyses found the associations held at three and five years. The cardiovascular signal is notably more modest than the hospitalization and mortality figures, which is worth sitting with rather than averaging away.

Limitations

This is a retrospective analysis of electronic health records, not a randomized trial, and the authors describe their findings as associations rather than effects. Propensity weighting balances measured characteristics only: people prescribed a GLP-1 may differ from those who are not in ways the records do not capture, and odds ratios this extreme in observational data usually invite that question. The authors conclude that prospective studies are warranted.

Where the question goes next

The study supports a potential role for GLP-1 receptor agonists in alcohol use disorder, in the authors' framing, without establishing one. Until a prospective trial runs, the size of these associations is the most interesting thing about them and also the main reason to be careful with them.

Source: European journal of internal medicine. Read the original.

Filed under: glp-1, celebrity, skin-beauty

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Sermorelin Goes Mainstream on Telehealth, but the Dosing and Efficacy Data Are Missing

Sermorelin, a peptide that stimulates growth-hormone release, is now sold nationally through Hims and Hers as part of its compounded Peptides+ platform. Neither the company nor the outside experts quoted can point to human outcome trials or an established dose.

Karnataka Regulators Cancel a Bengaluru Peptide Party as India's Longevity Market Accelerates

Karnataka's drug regulator canceled a Bengaluru "Peptide Party" on August 29 and questioned the organizers about ingredients, legality and health claims. The Indian Express reports the shutdown against a biohacking market Grand View Research valued at $1.21 billion in 2025.

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Semaglutide has large human trials behind its weight and metabolic outcomes, but the newer questions about energy expenditure, muscle preservation and cognition are far less settled. A digest of what researchers have actually reported, and where the evidence stops.